rifaximin has been researched along with Gastroenteritis* in 1 studies
1 other study(ies) available for rifaximin and Gastroenteritis
Article | Year |
---|---|
Antimicrobial activity of prulifloxacin tested against a worldwide collection of gastroenteritis-producing pathogens, including those causing traveler's diarrhea.
Prulifloxacin, the prodrug of ulifloxacin (active component), is a newer fluoroquinolone with broad activity against enteric and nonenteric gram-negative bacilli. Ulifloxacin and other oral comparator agents were tested for activity against 582 gastroenteritis strains from global surveillance studies. Ulifloxacin was highly active against Escherichia coli, Salmonella spp., Shigella spp., Yersinia spp., Vibrio spp., Aeromonas spp., and Plesiomonas spp. (MIC(50)s and MIC(90)s, Topics: Anti-Bacterial Agents; Diarrhea; Dioxolanes; Fluoroquinolones; Gastroenteritis; Gram-Negative Bacteria; Humans; Piperazines; Population Surveillance; Prodrugs | 2009 |